Cargando…
Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828
Autores principales: | Kohsaka, Shun, Okami, Suguru, Morita, Naru, Yajima, Toshitaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095320/ https://www.ncbi.nlm.nih.gov/pubmed/37048834 http://dx.doi.org/10.3390/jcm12072578 |
Ejemplares similares
-
Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia
por: Kohsaka, Shun, et al.
Publicado: (2022) -
Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan
por: Kashihara, Naoki, et al.
Publicado: (2019) -
Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan
por: Kanda, Eiichiro, et al.
Publicado: (2020) -
Cardiovascular and Renal Outcomes Associated With Hyperkalemia in Chronic Kidney Disease: A Hospital-Based Cohort Study
por: Kohsaka, Shun, et al.
Publicado: (2021) -
Machine Learning Models Predicting Cardiovascular and Renal Outcomes and Mortality in Patients with Hyperkalemia
por: Kanda, Eiichiro, et al.
Publicado: (2022)